---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-031794"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2023-06-28T23:59:59+00:00"
generated_at: "2026-06-13T15:33:06.271887+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Roivant Q4/FY2023: VTAMA net rev $13.7M, $28.0M FY; RVT-3101 UC data positive; cash $1.7B; FY loss $1.23B

## Summary
- VTAMA net product revenue $13.7M in Q4, $28.0M FY; 170k prescriptions since launch; 76% US commercial lives covered.
- RVT-3101 improved efficacy from week 14 to week 56 in Phase 2b UC study; Phase 2 Crohn's initiated, data expected Q4 2024.
- VTAMA met primary and all secondary endpoints in Phase 3 ADORING 1/2 for atopic dermatitis in 813 patients including children aged 2+.
- Cash and equivalents $1.7B at March 31, 2023; cash runway into H2 2025. GAAP loss from continuing ops $175M Q4 ($0.20/share).
- FY2023 GAAP loss from continuing ops $1.23B ($1.58/share); net loss attributable to Roivant $1.01B.

## SEC filing metadata
- accession: 0001140361-23-031794
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2023-06-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036123031794/0001140361-23-031794-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036123031794/brhc20054989_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-031794
- JSON: https://secwatch.observer/filing/0001140361-23-031794.json
- Plain text: https://secwatch.observer/filing/0001140361-23-031794.txt

## Key facts
- Earnings Releases
  Roivant Sciences Ltd. reported financial results for the fourth quarter and fiscal year ended March 31, 2023.
  - Period: the fourth quarter and fiscal year ended March 31, 2023
  - Result: reported results
  source text: On June 28, 2023, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1635088/000114036123031794/0001140361-23-031794-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.